DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced an equity investment by the Merck Global Health Innovation Fund (GHIF), the corporate venture capital arm of Merck & Co., Inc, known as MSD outside the United States and Canada. The capital will accelerate and expand DELFI's development and commercialization of its cancer detection solutions. DELFI's fragmentomics technology applies artificial intelligence (AI) to whole-genome sequencing data to compare an individual's cell-free DNA (cfDNA) patterns and characteristics against populations with and without cancer.
Oxford Nanopore Technologies has launched a new Pharmacogenomics (PGx) Beta Program with Twist Biosciences.
A team led by researchers at the University of Michigan has developed and clinically validated an 18-gene urinary test for detecting high-grade prostate cancer.
The House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party said on Thursday that it has introduced a new bill to ban the use of federal funding on "foreign adversary biotech companies," including China's BGI Group.
New research suggests a combination of molecular profiling on tumor tissue and corresponding circulating tumor DNA (ctDNA) samples can provide clinically actionable clues that may be missed using either approach alone, particularly for individuals with breast cancer or non-small cell lung cancer (NSCLC).
Chinese molecular diagnostic firm Dinfectome said on Monday that its DIFSeq-200 sequencer has obtained approval from the Chinese National Medical Products Administration (NMPA).
Roswell Park Cancer Center said this week that Agilent Technologies has licensed its blood cancer assay, PanHeme.
Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, today announced a collaboration to introduce workflow solutions that save time and effort required for genomic analysis of samples.
Agilent Technologies Inc. (NYSE: A) recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years.
MGI Tech said on Thursday that it has signed a memorandum of understanding with South Korean life science tools distributor Bio-Medical Science (BMS) to bring its next-generation sequencing products to South Korea.
✔ All (30)
✔ Press release (0)
✔ Industry news (30)
Don’t miss important updates about the show and the in vitro diagnostic industry.
Sign-up for our newsletter today.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.